Acupoint Application in Patients With Stable Angina Pectoris (AASAP) (AASAP)
Effect of Acupoint Application With Herbal Medicine in Patients With Stable Angina Pectoris: Randomized, Controlled,Double Blind Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610072
- Affiliated Hospital of Chengdu University of TCM
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1.Meet the diagnostic criteria of American College of Cardiology(ACC)/American Heart Association (AHA) angina pectoris of coronary heart disease.
2.35 ≤ age ≤ 85 years, both male and female.
3.The onset of angina pectoris≥3 months, and the frequency of angina attack≥2 a week.
4.Patients signed the informed consent
Exclusion Criteria:
- age≤35 or age≥85.
- Pregnant women or women in lactation or women of child bearing potential plan to conceive in the recent six months.
- history of diabetes.
- Co-infection or bleeding, allergic.
- Currently participating in other clinical trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Herbal application on acupoint group
Containing the herbal medicine application on the specific acupoints plus foundation treatment
|
Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
Other Names:
select acupoint according to traditional Chinese medicine
Other Names:
foundation treatment
Other Names:
|
|
Placebo Comparator: Placebo application on acupoint
Not containing herbal medicine application on the specific acupoints plus foundation treatment
|
select acupoint according to traditional Chinese medicine
Other Names:
foundation treatment
Other Names:
|
|
Placebo Comparator: Herbal application on non-acupoint group
Containing the herbal medicine application on the non-acupoints plus foundation treatment
|
Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
Other Names:
foundation treatment
Other Names:
|
|
Sham Comparator: Placebo application on non-acupoint
Not containing herbal medicine application on the non-acupoints plus foundation treatment
|
foundation treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline Number of angina attacks at 12 weeks
Time Frame: at baseline,4, 8weeks after inclusion
|
The change frequency of angina attack during every 4-week.
|
at baseline,4, 8weeks after inclusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline the severity of angina ( VAS score) at 12 weeks
Time Frame: at baseline,4, 8weeks after inclusion
|
The VAS score evaluation angina pain severity
|
at baseline,4, 8weeks after inclusion
|
|
Change from Baseline the dosage of nitroglycerin at 12 weeks
Time Frame: at baseline,4, 8weeks after inclusion
|
Observed reduction in the dose of nitroglycerin
|
at baseline,4, 8weeks after inclusion
|
|
Seattle Angina Questionnaire
Time Frame: at baseline,4, 8weeks after inclusion
|
at baseline,4, 8weeks after inclusion
|
|
|
self-rating anxiety scale
Time Frame: at baseline,4, 8weeks after inclusion
|
at baseline,4, 8weeks after inclusion
|
|
|
Self-rating Depression Scale
Time Frame: at baseline,4, 8weeks after inclusion
|
at baseline,4, 8weeks after inclusion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Fanrong Liang, Chengdu University of TCM
Publications and helpful links
General Publications
- Li DH, Xie J, Ren YL, Zheng H, Lyu JL, Leng JY, Zhang LL, Zhang J, Fan HL, Liang FR. Effectiveness and Safety of Acupoint Application of Guan Xin Su He Pill () for Patients with Chronic Stable Angina Pectoris: A Multi-Center, Randomized Controlled Trial. Chin J Integr Med. 2021 Nov;27(11):838-845. doi: 10.1007/s11655-021-2870-3. Epub 2021 Aug 13.
- Ren Y, Li D, Zheng H, Lv J, Leng J, Zhang L, Zhang J, Fan H, Liang F. Acupoint application in patients with chronic stable angina pectoris: study protocol of a randomized, double-blind, controlled trial. Evid Based Complement Alternat Med. 2014;2014:619706. doi: 10.1155/2014/619706. Epub 2014 Aug 27.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Pain
- Neurologic Manifestations
- Chest Pain
- Angina Pectoris
- Angina, Stable
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Antimetabolites
- Protease Inhibitors
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Angiotensin-Converting Enzyme Inhibitors
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Aspirin
- Atorvastatin
- Metoprolol
- Ramipril
Other Study ID Numbers
Other Study ID Numbers
- 2011SZ0302.2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.